Protein S-acylation dynamics provide metabolic plasticity to acute myeloid leukemia cells

This study reveals that the synthetic lethality observed in acute myeloid leukemia cells upon combined glutaminase and TOFA inhibition stems from TOFA's non-canonical blockade of protein S-acylation, a mechanism essential for maintaining mitochondrial respiration in cancer cells but dispensable in healthy hematopoietic progenitors, thereby exposing a unique metabolic vulnerability for targeted therapy.

The Gist

Imagine Acute Myeloid Leukemia (AML) cells as a group of very stubborn, high-energy athletes who have forgotten how to run a marathon. Instead, they rely entirely on one specific energy drink (a nutrient called glutamine) to keep their engines running. If you take away that drink, they usually panic and find a way to switch to a backup generator (like burning fat or sugar) to survive. This ability to switch fuels is called metabolic plasticity, and it's why cancer is so hard to kill; if you block one path, they just take a detour.

This study discovered a clever way to trap these cancer cells so they can't escape. Here is the story of how they did it, explained simply:

1. The Two-Pronged Attack

The researchers tried a "tag team" approach. They used two different drugs:

• Drug A (BPTES): This blocks the main energy drink (glutamine). It's like cutting off the water supply to a factory.
• Drug B (TOFA): This is an old drug originally used to lower cholesterol. The researchers thought it might block the factory's ability to make its own fuel (fats).

The Surprise: When they used Drug A alone, the cancer cells switched to a backup generator and survived. When they used Drug B alone, the cells were fine. But when they used both together, the cancer cells died rapidly. It was a "synthetic lethality"—a situation where two harmless things become deadly when combined.

2. The Real Villain: The "Glue"

Here is the twist: The researchers expected Drug B (TOFA) to work by stopping fat production. But they found it wasn't doing that at all.

Instead, TOFA was acting like a glue remover.
Inside our cells, there are tiny "glue guns" (enzymes called S-acyltransferases) that attach fatty acid "glue" to important proteins. This glue is essential for those proteins to stick to the cell's power plants (mitochondria) and keep them working.

• In Healthy Cells: These cells are like Swiss Army knives. They are flexible. If you cut off their water supply, they can easily switch to solar power, wind power, or battery power. They don't rely heavily on that specific "glue" to survive.
• In Cancer Cells: These cells are like a single-purpose machine. They are so dependent on their specific power plant that they need that "glue" to keep the machine running. When Drug A cuts off the water, the cancer cells try to panic and re-glue their proteins to switch to a backup fuel. But Drug B (TOFA) removes the glue. The proteins fall off, the power plant collapses, and the cell dies.

3. The "Long Chain" Requirement

The study also found that the cancer cells are picky eaters. They specifically need long, straight fatty acids (like 16-to-18 carbon chains) to make that "glue" work.

• If you feed the cancer cells a mix of these specific fats, they can survive the drug attack.
• If you feed them different types of fats (like the ones found in fish oil), it actually makes them die faster.

This is like realizing the cancer machine only runs on a specific brand of gasoline. If you block the pump (Drug A) and pour water in the tank instead of the right gasoline (Drug B), the engine explodes.

4. Why This Matters

The most exciting part is that healthy blood cells (the good guys) didn't care about this combination. They have too many backup plans and don't rely on this specific "glue" mechanism. This means the treatment could kill the leukemia without hurting the patient's healthy bone marrow.

The Big Picture Analogy

Think of the cancer cell as a house built on a single, shaky foundation.

• Drug A removes the roof (the main energy source).
• Drug B removes the nails holding the walls together (the protein glue).
• Healthy cells are like a tent. If you take away the roof, they just set up a new tent or move inside. They are flexible.
• Cancer cells are like that house. Without the roof, they try to reinforce the walls, but if you remove the nails at the same time, the whole house collapses instantly.

Conclusion: This paper shows that by understanding how cancer cells "glue" their machinery together to survive stress, we can find a way to break that glue and stop them from adapting. It opens the door to new treatments that target the cancer's inability to be flexible, rather than just trying to starve it.

Technical Summary

1. Problem Statement

Acute Myeloid Leukemia (AML) remains a challenging disease with high relapse rates and limited long-term survival, largely due to metabolic plasticity. Cancer cells can rewire their metabolism to survive the inhibition of single pathways (e.g., glutaminolysis or oxidative phosphorylation). While targeting metabolic dependencies like glutaminolysis (via Glutaminase inhibitors) has shown promise, clinical success has been limited because AML cells adapt by switching to alternative fuel sources. The study aims to identify a combinatorial strategy to block this metabolic adaptability and induce synthetic lethality in AML cells while sparing healthy hematopoietic stem and progenitor cells (HSPCs).

2. Methodology

The researchers employed a multi-faceted approach combining high-throughput screening, stable isotope tracing, lipidomics, proteomics, and functional metabolic assays:

• Combinatorial Screening: An in vitro screen tested 11 metabolic inhibitors (targeting glycolysis, glutaminolysis, lipogenesis, OXPHOS, etc.) in various pairwise combinations across multiple AML cell lines and healthy HSPCs.
• Metabolic Tracing: Stable isotope tracing using $^{13}$C-glutamine and $^{13}$C-glucose was used to map carbon flux through the TCA cycle and de novo lipogenesis pathways.
• Lipidomics & Metabolomics: Untargeted LC-MS and GC-MS analyses were performed to characterize changes in lipid species (saturation levels, cardiolipins) and metabolite pools upon drug treatment.
• Mechanistic Target Identification:
  • CRISPR & RNA-seq Data Mining: Used DepMap data to identify enzymes dependent on long-chain fatty acyl-CoAs that are essential for AML survival.
  • Biochemical Assays: Acyl-biotin exchange and click chemistry assays were used to measure global protein S-acylation (palmitoylation) levels.
  • Rescue Experiments: Supplementation with specific fatty acids (SFA/MUFA vs. PUFA) to determine if cell death was driven by lipid depletion or specific signaling defects.
• Functional Metabolic Assays: Seahorse XF analysis (OCR/ECAR) to measure mitochondrial respiration and glycolysis; Dynamic BH3 profiling to assess apoptotic priming in primary patient samples.
• Proteomics: Mass spectrometry of S-acylated proteins (via streptavidin pull-down) to identify specific substrates affected by the drug combination.

3. Key Contributions & Findings

A. Discovery of Synthetic Lethality

The study identified a potent synthetic lethal interaction between BPTES (a glutaminase/GLS inhibitor) and TOFA (5-(tetradecyloxy)-2-furoic acid), a hypolipidemic agent.

• Selectivity: The combination induced synergistic apoptosis in multiple AML cell lines and primary patient-derived blasts (including leukemic stem cells) but had no cytotoxic effect on healthy cord blood or bone marrow-derived HSPCs.
• Mechanism of Death: Cell death was confirmed to be apoptotic (Caspase-3 activation, BH3 profiling) rather than ferroptotic, despite initial hypotheses regarding lipid peroxidation.

B. Redefining the Role of TOFA

While TOFA is canonically known as an inhibitor of Acetyl-CoA Carboxylase (ACC) and de novo lipogenesis, the authors demonstrated that:

• ACC Inhibition is Not the Driver: Other potent ACC inhibitors (ND-646, PF-05175157) and genetic knockdown of ACC1 did not replicate the cytotoxic synergy with BPTES.
• Non-Canonical Target: TOFA acts as a potent inhibitor of protein S-acyltransferases (zDHHC enzymes). It blocks the attachment of long-chain fatty acids (specifically C16:0 and C18:0) to proteins.
• Evidence: TOFA treatment significantly reduced global protein S-palmitoylation in AML cells, an effect mimicked by the known zDHHC inhibitor 2-BP.

C. Metabolic Plasticity via S-Acylation

The core finding is that AML cells rely on dynamic protein S-acylation to survive glutaminolysis inhibition.

• Adaptive Response: When GLS is inhibited (by BPTES), AML cells increase the S-acylation of specific metabolic enzymes (e.g., glycolytic enzymes like GAPDH, PKM, and mitochondrial proteins like MDH2 and AK2). This modification likely facilitates metabolic rewiring or mitochondrial coupling to maintain respiration.
• The "Straw that Breaks the Camel's Back": TOFA inhibits the zDHHC enzymes required for this adaptive S-acylation. Consequently, when GLS is blocked, the cells cannot upregulate the necessary S-acylated proteins to maintain mitochondrial function, leading to a collapse in OXPHOS and ATP production.
• Fatty Acid Specificity: The rescue of cell death by exogenous fatty acids required 16-to-18 carbon saturated and monounsaturated fatty acids (e.g., oleic acid), not polyunsaturated fatty acids (PUFAs). This suggests the requirement is for the specific substrates of zDHHC enzymes, not just membrane saturation.

D. Differential Metabolic Flexibility

Healthy HSPCs possess inherent metabolic flexibility that AML cells lack.

• HSPCs can switch between glucose, glutamine, and fatty acid oxidation to fuel OXPHOS without requiring changes in global protein S-acylation.
• AML cells are "addicted" to S-acylation dynamics to maintain mitochondrial respiration under stress, making them uniquely vulnerable to the BPTES/TOFA combination.

4. Results Summary

• Viability: BPTES + TOFA caused >80% cell death in AML lines (NOMO1, MOLM14, etc.) and primary AML samples, with CDI (Coefficient of Drug Interaction) < 0.7 (synergistic). Healthy HSPCs remained viable.
• Metabolic Flux: BPTES blocked glutamine entry into the TCA cycle. TOFA blocked de novo lipogenesis but did not cause ferroptosis. The combination led to a massive accumulation of upstream glycolytic metabolites and a collapse in TCA cycle intermediates.
• Mitochondrial Function: The combination caused a synergistic drop in Oxygen Consumption Rate (OCR) and mitochondrial membrane potential, leading to ATP depletion.
• Proteomics: Identified ~382 S-acylated proteins. BPTES treatment increased S-acylation of glycolytic and mitochondrial proteins (Class 2), which was blocked by TOFA. TOFA also reduced S-acylation of other mitochondrial proteins (Class 3) regardless of BPTES.
• Rescue: Exogenous SFA/MUFA supplementation restored viability and metabolic intermediates, confirming the dependency on specific fatty acid pools for S-acylation.

5. Significance

• Therapeutic Strategy: This study proposes a novel therapeutic window where targeting protein S-acylation dynamics (via TOFA or similar agents) can sensitize AML cells to metabolic inhibitors (like GLS inhibitors), overcoming the resistance caused by metabolic plasticity.
• Mechanistic Insight: It reveals that protein S-acylation is not just a structural modification but a critical regulatory mechanism for metabolic adaptation in cancer.
• Re-evaluation of TOFA: The findings necessitate a re-evaluation of previous studies using TOFA as a specific ACC inhibitor, as its cytotoxic effects in cancer may be largely driven by zDHHC inhibition.
• Broad Applicability: While focused on AML, the synthetic lethality was also observed in other cancer types (e.g., breast cancer MCF7), suggesting a potential pan-cancer vulnerability related to metabolic inflexibility and S-acylation dependency.

In conclusion, the paper identifies protein S-acylation as a critical node of metabolic plasticity in AML. By combining a glutaminase inhibitor with an S-acyltransferase inhibitor (TOFA), the study successfully blocks the cancer cell's ability to adapt, inducing mitochondrial collapse and apoptosis while sparing healthy cells that possess intrinsic metabolic flexibility.